Open AccessSox2‐dependent inhibition of p21 is associated with poor prognosis of endometrial cancer
Author(s) -
Yamawaki Kaoru,
Ishiguro Tatsuya,
Mori Yutaro,
Yoshihara Kosuke,
Suda Kazuaki,
Tamura Ryo,
Yamaguchi Masayuki,
Sekine Masayuki,
Kashima Katsunori,
Higuchi Masaya,
Fujii Masahiro,
Okamoto Koji,
Enomoto Takayuki
Publication year - 2017
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13196
Subject(s) - endometrial cancer , sox2 , cancer research , biomarker , embryonic stem cell , cancer , medicine , cell growth , oncology , biology , gene , genetics
Sex‐determining region Y‐box 2 ( SOX 2) is an essential factor involved in the self‐renewal and pluripotency of embryonic stem cells and has functions in cell survival and progression in many types of cancers. Here, we found that several endometrial cancer cell lines expressed SOX 2, which was required for cell growth. Additionally, SOX 2 overexpression regulated the expression of cyclin‐dependent kinase inhibitor 1A ( CDKN 1A ), and SOX 2 specifically bound to p21 promoter DNA in endometrial cancer cell lines expressing SOX 2. Expressions of SOX 2 in endometrial cancer patients were significantly correlated with histological grade and poor prognosis. Moreover, low p21 together with high SOX 2 expressions in advanced endometrial cancer patients were associated with the most unfavorable outcomes of patients. These results indicated that simultaneous measurement of SOX 2 and p21 expression in endometrial cancer patients may be a useful biomarker for patient prognosis.